Novartis Plans Major Investment In All Drug Making Aspects In China
This article was originally published in PharmAsia News
Executive Summary
Swiss drug maker Novartis plans a major investment in China covering all aspects of selling pharmaceuticals in the country. Part of the planned investment includes greater emphasis on recruiting staff as its Chinese facilities expand, in part to launch six new drugs and conduct clinical trials this year. The CEO of Novartis Pharmaceuticals Division, Joseph Jimenez, said the company was continuing to put more money into its research and development center in Shanghai. Jimenez declined to set a figure on the investment, but said it would be considerable. (Click here for more
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.